Instability of tuberculin and candida skin test reactivity in HIV- infected Ugandans

American Journal of Respiratory and Critical Care Medicine

Volumn 158, Issue 6, 1998, Pages 1790-1796

  Johnson, John L ^a   Nyole, Sam ^b   Okwera, Alphonse ^b   Whalen, Christopher C ^b   Nsubuga, Peter ^b   Pekovic, Vukosava ^b   Huebner, Robin ^b   Wallis, Robert S ^b   Mugyenyi, Peter N ^b   Mugerwa, Roy D ^b   Ellner, Jerrold J ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA ANTIGEN; GAMMA INTERFERON; ISONIAZID; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDA; CLINICAL TRIAL; CLONAL ANERGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PROCEDURES; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; TUBERCULIN TEST; TUBERCULOSIS; UGANDA;

EID: 0032415590     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.158.6.9803104     Document Type: Article

References (33)

1. Narain, J. P., M. C. Raviglione, and A. Kochi. 1992. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber. Lung Dis. 73:311-321.
2. Raviglione, M. C., J. P. Narain, and A. Kochi. 1992. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. Bull. World Health Organ. 70:515-526.
3. Pape, J. W., S. S. Jean, J. L. Ho, A. Hafner, and W. D. Johnson, Jr. 1993. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 342:268-272.
4. Wadhawan, D., S. Hira, N. Mwansa, R. Sunkutu, T. Adera, and P. Perine. 1993. Preventive tuberculosis chemotherapy with isoniazid (INH) among patients infected with HIV-1. Abstract PO-BO7-1114. IX International Conference on AIDS. Berlin, Germany, June 6-11, 1993.
5. Whalen, C. C., J. L. Johnson, A. Okwera, D. L. Hom, R. Huebner, P. Mugyenyi, R. D. Mugerwa, J. J. Ellner, and the Uganda-Case Western Reserve University Research Collaboration. 1997. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N. Engl. J. Med. 337:801-808.
6. Centers for Disease Control. 1991. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. Morb. Mortal. Wkly. Rep. 40(RR-5):27-33.
7. Bass, J. B., Jr., L. S. Farer, P. C. Hopewell, R. O'Brien, R. F. Jacobs, F. Ruben, D. E. Snider, Jr., and G. Thornton. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 149:1359-1374.
8. Chin, D. P., D. Osmond, K. Page-Shafer, J. Glassroth, M. J. Rosen, L. B. Reichman, P. A. Kvale, J. M. Wallace, W. K. Poole, P. C. Hopewell and the Pulmonary Complications of HIV Study Group. 1996. Reliability of anergy skin testing in persons with HIV infection. Am. J. Respir. Crit. Care Med. 153:1982-1984.
9. Centers for Disease Control and Prevention. 1997. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. Morb. Mortal. Wkly. Rep. 46(RR-15):1-8.
10. Global Tuberculosis Programme/World Health Organization. 1997. Global Tuberculosis Control. World Health Organization, Geneva, Switzerland. WHO publication no. WHO/TB/97.225.
11. Stott, H., A. Patel, I. Sutherland, I. Thorup, P. G. Smith, P. W. Kent, and Y. P. Rykushin. 1973. The risk of tuberculous infection in Uganda, derived from the findings of national tuberculin surveys in 1958 and 1970. Tubercle 34:1-22.
12. Flesch, I., and S. H. Kaufmann. 1987. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J. Immunol. 138:4408-4413.
13. Rook, G. A., J. Steele, M. Ainsworth, and B. R. Champion. 1986. Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology 59:333-338.
14. Flesch, I. E., and S. H. Kaufmann. 1990. Activation of tuberculostatic macrophage functions by gamma interferon, interleukin-4, and tumor necrosis factor. Infect. Immun. 58:2675-2677.
15. Kindler, V., A. P. Sappino, G. E. Grau, P. F. Piguet, and P. Vassalli. 1989. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731-740.
16. Karnofsky, D. A., and J. H. Burchenal. 1949. The clinical evaluation of chemotherapeutic agents in cancer. In C. M. MacLeod, editor. Evaluation of Chemotherapeutic Agents. Columbia University Press, New York. 191-205.
17. World Health Organization. 1990. Acquired immunodeficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly. Epiclemiol. Rec. 65:221-222.
18. Hecker, M. T., J. L. Johnson, C. C. Whalen, S. Nyole, R. D. Mugerwa, and J. J. Ellner. 1997. Two-step tuberculin skin testing in HIV-infected persons in Uganda. Am. J. Respir. Cril. Care Med. 155:81-86.
19. Smedman, L., A. Joki, P. Perlmann, and M. T. Blomberg. 1991. Whole-blood microassay for immunodetection of antigen specific cell mediated immunity using bromodeoxyuridine incorporation. J. Clin. Lab. Immunol. 34:79-85.
20. Bloemena, E., M. T. Roos, J. L. Van Heijst, J. M. Vossen, and P. T. Schellekens. 1989. Whole-blood lymphocyte cultures. J. Immunol. Methods 122:161-167.
21. Wallis, R. S., R. Paranjape, and M. Phillips. 1993. Identification by two-dimensional gel electrophoresis of a 58-kilodalton tumor necrosis factor-inducing protein of Mycobacterium tuberculosis. Infect. Immun. 61:627-632.
22. 2-microglobulin levels in different stages of human immunodeficiency virus infection. J. Lab. Clin. Immunol. 17:133-137.
23. Okwera, A., P. P. Eriki, L. A. Guay, and T. M. Daniel. 1990. Tuberculin reactions in apparently healthy HIV-seropositive and HIV-seronegative women: Uganda. Morb. Mortal. Wkly. Rep. 39:638-639, 645-646.
24. Markowitz, N., N. I. Hansen, T. C. Wilcosky, P. C. Hopewell, J. Glassroth, P. A. Kvale, B. T. Mangura, D. Osmond, J. M. Wallace, M. J. Rosen, L. B. Reichman, and the Pulmonary Complications of HIV Infection Study Group. 1993. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann. Intern. Med. 119:185-193.
25. Graham, N. M. H., K. E. Nelson, L. Solomon, M. Bonds, R. T. Rizzo, J. Scavotto, J. Astemborski, and D. Vlahov. 1992. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. J.A.M.A. 267:369-373.
26. Johnson, M. P., J. S. Coberly, H. C. Clermont, R. E. Chaisson, H. L. Davis, P. Losikoff, A. J. Ruff, R. Boulos, and N. A. Halsey. 1992. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J. Infect. Dis. 166:194-198.
27. Yanai, H., W. Uthaivoravit, T. D. Mastro, K. Limpakarnajanarat, P. Sawanpanyalert, R. H. Morrow, Jr., and P. Nieburg. 1997. Utility of tuberculin and anergy skin testing in predicting tuberculosis infection in human immunodeficiency virus-infected persons in Thailand. Int. J. Tuberc. Lung Dis. 1:427-434.
28. Colebunders, R. L., I. Lebughe, N. Nzila, D. Kalunga, H. Francis, R. Ryder, and P. Piot. 1989. Cutaneous delayed-type hypersensitivity in patients with human immunodeficiency virus infection in Zaire. J. Acquir. Immune Def. Syndr. 2:576-578.
29. Selwyn, P., B. Sckell, P. Alcabes, G. Friedland, R. Klein, and E. Schoenbaum. 1992. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. J.A.M.A. 268:504-509.
30. Moreno, S., J. Baraia-Etxaburu, E. Bouza, F. Parras, M. Perez-Tascon, P. Miralles, T. Vicente, J. Alberdi, J. Cosin, and D. Lopez-Gay. 1993. Risk for developing tuberculosis among anergic patients infected with HIV. Ann. Intern. Med. 119:194-198.
31. Gordin, F. M., J. P. Matts, C. Miller, L. S. Brown, R. Hafner, S. L. John, M. Klein, A. Vaughn, C. L. Besch, G. Perez, S. Szabo, and W. El-Sadr for the Terry Beirn Community Programs for Clinical Research on AIDS. 1997. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N. Engl. J. Med. 337:315-320.
32. Caiaffa, W. T., N. M. H. Graham, N. Galai, R. T. Rizzo, K. E. Nelson, and D. Vlahov. 1995. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch. Intern. Med. 155:2111-2117.
33. Thompson, N. J., J. L. Glassroth, D. E. Snider, Jr., and L. S. Farer. 1979. The booster phenomenon in serial tuberculin testing. Am. Rev. Respir. Dis. 119:587-597.